Marques Sílvio Alencar, Camargo Rosangela Maria Pires de
Department of Infectology, Dermatology, Diagnostic Imaging and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil.
Department of Infectology, Dermatology, Diagnostic Imaging and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil.
An Bras Dermatol. 2025 Jan-Feb;100(1):12-21. doi: 10.1016/j.abd.2024.07.004. Epub 2024 Nov 15.
Cryptococcosis is a disease caused by fungi of the genus Cryptococcus, with the species Cryptococcus neoformans and Cryptococcus gattii being recognized as pathogenic. Cutaneous cryptococcosis can be classified as "secondary", developing from a previous systemic disease, or, on the contrary, "primary", resulting from transcutaneous inoculation of the agent. It can also be classified as "disseminated cutaneous cryptococcosis", when there is an associated systemic disease, or "localized", when it is restricted to the skin. This article uses the term "primary cutaneous cryptococcosis" because it is the most widely used and already established in the literature. Historically, the first report of a possible case of primary cutaneous cryptococcosis (PCC) occurred in 1950 by Gancy WM and was published in the Archives of Dermatology and Syphilology. Subsequently, the rare and sporadic reports in the following decades were reviewed and reported in the 1985 publication by Baes & van Cutsen. However, the unequivocal acceptance of the existence of PCC as a distinct disease only occurred in 2003 with the publication by Neville S et al. of the French Cryptococcosis Study Group. The fundamental criterion established to consider it as PCC was the proven absence of systemic disease, whether pulmonary, in the CNS or other location at the time of diagnosis of the cutaneous condition, characterized by a single lesion and, mostly, in an exposed area. These and other clinical criteria, diagnostic confirmation, and therapeutic choice are discussed in detail in the full text.
隐球菌病是一种由隐球菌属真菌引起的疾病,新型隐球菌和格特隐球菌被认为是致病菌种。皮肤隐球菌病可分为“继发性”,由先前的全身性疾病发展而来,或者相反,“原发性”,由病原体经皮接种引起。当存在相关的全身性疾病时,它也可分为“播散性皮肤隐球菌病”,或者当局限于皮肤时,称为“局限性”。本文使用“原发性皮肤隐球菌病”这一术语,因为它是文献中使用最广泛且已确立的术语。历史上,1950年Gancy WM首次报告了一例可能的原发性皮肤隐球菌病(PCC)病例,并发表于《皮肤病学与梅毒学档案》。随后,在接下来的几十年里,罕见且零星的报告在1985年Baes & van Cutsen的出版物中得到回顾和报道。然而,直到2003年法国隐球菌病研究组的Neville S等人发表文章,PCC作为一种独特疾病才被明确认可。将其视为PCC所确立的基本标准是,在诊断皮肤病症时,经证实不存在全身性疾病,无论是肺部、中枢神经系统还是其他部位的疾病,其特征为单个病灶,且大多位于暴露部位。这些以及其他临床标准、诊断确认和治疗选择将在全文中详细讨论。